Elizabeth Pan1, Lily Tung2, Omar Ragab3, Elise Morocco1, Julie Wecsler2, Richard Sposto4, Akshara Raghavendra5, Eugene Chung3, Julie E Lang6. 1. Keck School of Medicine, University of Southern California, Los Angeles, CA, U.S.A. 2. Los Angeles County and University of Southern California Medical Center Department of Surgery and Norris Comprehensive Cancer Center, Division of Breast, Soft Tissue and Endocrine Surgery, University of Southern California, Los Angeles, CA, U.S.A. 3. Los Angeles County and University of Southern California Medical Center Department of Radiation Oncology and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, U.S.A. 4. Department of Preventive Medicine and Pediatrics of Children's Hospital of Los Angeles and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, U.S.A. 5. Department of Medicine, Division of Oncology, University of Southern California, Los Angeles, CA, U.S.A. 6. Los Angeles County and University of Southern California Medical Center Department of Surgery and Norris Comprehensive Cancer Center, Division of Breast, Soft Tissue and Endocrine Surgery, University of Southern California, Los Angeles, CA, U.S.A. julie.lang@med.usc.edu.
Abstract
BACKGROUND: Evidence on the management of inflammatory breast cancer (IBC) is limited. This study investigated factors influencing IBC treatment outcomes such as event-free survival (EFS) and overall survival (OS). MATERIALS AND METHODS: Data were collected from 173 patients with stage III non-IBC and 17 patients with IBC diagnosed at the Keck Medical Center and Los Angeles County and University of Southern California (LAC+USC) Medical Center. Cox proportional hazard regression evaluated associations between variables significant for EFS and OS. RESULTS: On multivariate analysis, negative estrogen receptor (ER)status [hazard ratio (HR)=1.88, 95% confidence interval (CI)=1.11-3.18, p<0.06) and lack of postoperative radiation treatment (HR=2.07, 95% CI=1.03-4.15, p<0.04) were significant for poorer EFS. High Scarff-Bloom-Richardson (SBR) score (HR=2.24, 95% CI=0.79-6.36, p<0.13) and lack of postoperative radiation treatment to the breast (HR=4.39, 95% CI=0.39-49.55, p<0.23) were associated with lower rates of OS. CONCLUSION: The diagnosis of IBC has a significantly worse prognosis. Receipt of post-mastectomy radiation therapy was a significant predictor of better EFS and OS. Copyright
BACKGROUND: Evidence on the management of inflammatory breast cancer (IBC) is limited. This study investigated factors influencing IBC treatment outcomes such as event-free survival (EFS) and overall survival (OS). MATERIALS AND METHODS: Data were collected from 173 patients with stage III non-IBC and 17 patients with IBC diagnosed at the Keck Medical Center and Los Angeles County and University of Southern California (LAC+USC) Medical Center. Cox proportional hazard regression evaluated associations between variables significant for EFS and OS. RESULTS: On multivariate analysis, negative estrogen receptor (ER)status [hazard ratio (HR)=1.88, 95% confidence interval (CI)=1.11-3.18, p<0.06) and lack of postoperative radiation treatment (HR=2.07, 95% CI=1.03-4.15, p<0.04) were significant for poorer EFS. High Scarff-Bloom-Richardson (SBR) score (HR=2.24, 95% CI=0.79-6.36, p<0.13) and lack of postoperative radiation treatment to the breast (HR=4.39, 95% CI=0.39-49.55, p<0.23) were associated with lower rates of OS. CONCLUSION: The diagnosis of IBC has a significantly worse prognosis. Receipt of post-mastectomy radiation therapy was a significant predictor of better EFS and OS. Copyright
Authors: N T Ueno; A U Buzdar; S E Singletary; F C Ames; M D McNeese; F A Holmes; R L Theriault; E A Strom; B J Wasaff; L Asmar; D Frye; G N Hortobagyi Journal: Cancer Chemother Pharmacol Date: 1997 Impact factor: 3.333
Authors: M Clarke; R Collins; S Darby; C Davies; P Elphinstone; V Evans; J Godwin; R Gray; C Hicks; S James; E MacKinnon; P McGale; T McHugh; R Peto; C Taylor; Y Wang Journal: Lancet Date: 2005-12-17 Impact factor: 79.321
Authors: Kenneth W Hance; William F Anderson; Susan S Devesa; Heather A Young; Paul H Levine Journal: J Natl Cancer Inst Date: 2005-07-06 Impact factor: 13.506
Authors: D J P van Uden; R Bretveld; S Siesling; J H W de Wilt; C F J M Blanken-Peeters Journal: Breast Cancer Res Treat Date: 2017-01-30 Impact factor: 4.872
Authors: Rory L Smoot; Cody A Koch; Amy C Degnim; Sylvester Sterioff; John H Donohue; Clive S Grant; Sunni A Barnes; Rachel E Gullerud; Timothy J Hobday; David R Farley Journal: Arch Surg Date: 2006-06
Authors: J Rouëssé; S Friedman; D Sarrazin; H Mouriesse; T Le Chevalier; R Arriagada; M Spielmann; A Papacharalambous; F May-Levin Journal: J Clin Oncol Date: 1986-12 Impact factor: 44.544
Authors: T Palangie; V Mosseri; J Mihura; F Campana; P Beuzeboc; T Dorval; E Garcia-Giralt; M Jouve; S Scholl; B Asselain Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Eleanor E R Harris; Delray Schultz; Helaine Bertsch; Kevin Fox; John Glick; Lawrence J Solin Journal: Int J Radiat Oncol Biol Phys Date: 2003-04-01 Impact factor: 7.038